Herceptin is an intravenous drug that is part of a chemotherapy regimen that is used to prevent recurrence ofbreast cancer, and for the treatment breastcancerthat has spread beyond the breast (metastasized). It belongs to a class ofdrugscalled monoclonal antibodies. Other monoclonal antibodies includ...
Trastuzumabcan commonly cause arashthat is usually not serious. However, you may not be able to tell it apart from a rarerashthat could be a sign of a severe reaction. Tell your doctor right away if you develop any rash. A very seriousallergic reactionto this drug is rare. However, get...
Thus, the authors proposed that elevated MUC4 expression masks the trastuzumab binding epitopes of HER2, resulting in steric hindrance of the interaction between this antibody and its therapeutic target, resulting in drug resistance. Interestingly, the authors also reported that HER2 was unable to ...
Thus, the authors proposed that elevated MUC4 expression masks the trastuzumab binding epitopes of HER2, resulting in steric hindrance of the interaction between this antibody and its therapeutic target, resulting in drug resistance. Interestingly, the authors also reported that HER2 was unable to ...
Drug class: HER2 inhibitors Breastfeeding En español Patient resources Trastuzumab drug information Trastuzumab-anns (Advanced Reading) Trastuzumab-dkst (Advanced Reading) Trastuzumab-dttb (Advanced Reading) Trastuzumab-pkrb (Advanced Reading) Trastuzumab-anns Other brands Herceptin, Trazimera, Kanjinti, ...
Trastuzumab is indicated for subcutaneous administration - in combination with either hyaluronidase15 or both hyaluronidase and pertuzumab20 - for the treatment of adults with HER2-positive breast cancers. Reduce drug development failure rates Build, train, & validate machine-learning modelswith evidence-...
To prevent medication errors, check the vial labels to ensure that the drug is trastuzumab and not trastuzumab emtansine. HER2 testing is mandatory for all conditions prior to initiation of therapy. This drug should only be initiated by a physician experienced in the administration of cytotoxic ...
ClassAntineoplastics; Immunotherapies; Monoclonal antibodies Mechanism of ActionAntibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; Immunomodulators Orphan Drug Status Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. ...
Food and Drug Administration (FDA) under accelerated approval based on objective response rate (ORR) data from KEYNOTE-811, and continued approval of this indication may be contingent upon verification and description of cli...
- 《European Journal of Cancer》 被引量: 257发表: 2001年 Antibody-drug conjugates: present and future. Antibody-drug conjugates () are becoming an increasingly important sub-class of antibody-related therapeutics. Two , brentuximab vedotin (Adcetris) and -tr... A Beck,V D’Atri,A Ehkirch,...